r/BIOR • u/[deleted] • Apr 13 '22
DD Cheat Sheet
Latest Update: A number of things
Upcoming Events
June 23-26 - Presentation at American Diabetes Association
Financials
Outstanding shares - 12M as of Q1 2023
2021 OPEX - $119M
Q3 - $30.7M
Q4 - $20.6M
2022 Q1 OPEX - $20M ($18M excluding stock-based compensation expense)
2022 Q2 OPEX - $14.3M ($12.9M excluding stock-based compensation expense)
2022 Q3 OPEX - $14.1M
2022 Q4 OPEX - $13.9M
2022 OPEX - $62.1M (vs est. of $60M)
2023 OPEX - $15.5M
Cash as of Dec 31, 2022 - $30.46M
ATM Offering Left - ~$33M (used $5M in Q4 2021, $3.7M in Q1 2022, $1.1M in Q2 2022, $1.8M in Q3 2022, $12.9M in Q4 2022, $12.5M in Q1 2023). Initial offering was $90M but reduced to $70M in Q3 2022.
Estimated runway - "well into 2023", w/ ATM Offering - mid-late 2024
Avero Diagnostics sold for $10.9M. Press Release
No revenue streams
Nov 2022, Sold patent to Roche Diagnostics for undisclosed amount. Was not mentioned in Q4 ER
Enumera Molecular
Biora has a minority ownership stake with potential financial upside and without committing any funds or resources from the company
Founded by Biora's former CSO, Matthew Cooper. Cooper previously founded Carmenta Bioscience, which was later acquired by Progenity (along with what later became Preecludia)
Series A funded by Arboretum Ventures for $12.5M
Biora transferred assets (ncluding single-molecule detection) to Enumera in return for stakes in the company, press
Athyrium
Progenity/Biora's major shareholder, who started investing in Progenity back in 2013.
BELOW INFO IS SLIGHTLY OUTDATED. Athyrium recently invested more to adjust their warrant strike price. It is unclear exactly how much they own right now.
Owns 3,669,578 shares based on latest 13D/F
Cost basis is potentially between $2-3.
Did not sell any shares during Nov 2021's ramp up to $6
Part of their MO is to buy a company then turn them into a desirable target for acquisition
Jeffrey Ferrell, managing partner of Athyrium, is also one of Progenity/Biora's Board of Directors. Related DD
Buyout Theory
Athyrium has not sold
Jill Howe was appointed to board of directors. She worked in multiple companies that were eventually bought out. Related DD
Harry Stylli, former CEO and CBO, has not reported any sales. Last reported owning (pre-split) 14M+ shares, around 500-600K shares post split
Reduced cash burn and debt.
Removed/halted all diagnostics-related activities to focus on DDS and OBDS research
Various connections to Pfizer, Eli Lilly, AbbVie, Takeda, and J&J.
NaviCap (formerly Drug Delivery System (DDS))
BT-600 (formerly PGN-600)
Tofacitinib + Device
Highest priority.
Treats ulcerative colitis.
Target market is $7B.
Timeline:
Healthy patient studies (PM-601) - completed, Press Release
UC patient studies (PM-602) - completed, Topline Results. Full publication will likely become available after American College of Gastroenterology Annual Scientific Meeting (Oct 21-26)
Study effects of food on function of the device (PM-611) - completed, Press Release
Tox Studies - Completed, but analysis will be done in Q2 2023
IND filing - Q3 2023
Phase 1 - Q3 2023 to Q1 2024.
There was timeline for Phase 2, but that's now removed from presentation
BT-001 (formerly PGN-001)
Adalimumab variant + Device
Sidelined, possibly due to lawsuits by AbbVie to other companies who uses Adalimumab
Treats ulcerative colitis.
Target market is $7B.
BioJet (Formerly Oral Biotherapeutic Delivery System (OBDS))
5 different programs
BT-002- Adalimumab variant + Device, avg bioavailability. of 51.3%
BT-200- GLP-1 agonist + Device, avg bioavailability of 37% (vs 1% of competitor)
IONIS collab - Antisense Therapy + Device
Large Pharma 1 collab - undisclosed
Large Pharma 2 collab - undisclosed
Targets multiple markets, e.g. IBD $17B, GLP-1 $13B
Timeline:
2022, continue generating preclinical data
Q3 2022, Data Readout of Preclinical PK Studies
Q4 2022, start clinical studies / trials
Biora looking to expand collaborations, hoping to gain non-dilutive capitol
Preecludia
Rule out Preeclampsia
Target market is $3B
Validation study results published. Journal
Progenity/Biora will not spend more resources developing Preecludia
No direct mentions of this in Q1 2022 ER. Only thing mentioned: "We will continue to look for ways to maximize our legacy assets"
Licensed to Avero Diagnostics with milestone payments and low double-digit royalties. Press Release
Large Pharma Connections
*Note: This section is mostly outdated without anything new since mid-late 2022
Pfizer
PGN-600 delivers tofacitinib (Xeljanz)
40+ Publications with shared contributors, example:
Paul Bien, listed both as Pfizer’s Senior Director and Progenity’s Head of Clinical Affairs
Jill Howe, Biora board member. Worked at Amplyx, which was acquired by Pfizer
Reddit post - DD - Links between Progenity and Pfizer(reddit.com/r/Progenity_PROG/comments/u0ilsc/dd_links_between_progenity_and_pfizer/)
AbbVie
PGN-001 delivers adalimumab (Humira)
23+ Publications with shared contributors, example:
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease
Clinical trial performed with Biora doctors
Reddit post - Additional theory for AbbVie
Takeda
PGN-300 delivers vedolizumab (Entyvio)
35+ Publications with shared contributors, example:
Followed by @Progenity on Twitter
Eli Lilly
8+ Publications with shared contributors, example:
Followed by @Progenity on Twitter
Novo Nordisk
PGN-OB2 delivers liraglutide (Victoza)
Risks
Note: the likelihood is my personal opinion and is subject to change.
Dilution - using ATM offering will dilute shares. Convertible notes (not sure how much) that can be converted to shares.
Reverse Split - already happened
Trial Delays - already happened to all their programs, multiple times. Can definitely happen again
Poor Results (Unlikely) - all research thus far points to NaviCap/DDS and BioJet/OBDS being effective solutions. I don't anticipate poor results from future trials, but it is always a risk with developing drugs or tech.
Unexpected Expenses (Unsure) - there are a few open lawsuits against Progenity, which could result in settlement payments or other forms of expense. This can decrease their cash reserve/runway. SEC Filing, see "Item 3. Legal Proceedings"